Report Sections

See All Reports

Coronavirus Infections (840) Severe Acute Respiratory Syndrome (575) Infection (491) Pneumonia (381) Communicable Diseases (217) Respiratory Distress Syndrome, Adult (187) Acute Lung Injury (148) Respiratory Distress Syndrome, Newborn (148) (134) Syndrome (129) Virus Diseases (98) Depression (92) Pneumonia, Viral (81) Critical Illness (69) Anxiety Disorders (57) Neoplasms (47) Respiratory Tract Infections (46) Disease (41) Diabetes Mellitus (39) Cardiovascular Diseases (38) Stress Disorders, Post-Traumatic (38) Emergencies (36) Wounds and Injuries (36) Depressive Disorder (35) Inflammation (35) Lung Diseases (33) Stress Disorders, Traumatic (33) Stress, Psychological (33) Respiratory Tract Diseases (31) Hypoxia (30) Lung Injury (30) Acute Kidney Injury (29) Mental Disorders (29) Thrombosis (29) Influenza, Human (27) Hypertension (25) Respiration Disorders (23) Disease Progression (22) Fibrosis (22) Cognitive Dysfunction (21) Olfaction Disorders (21) Arthritis (20) Diabetes Mellitus, Type 2 (20) Sclerosis (20) Burnout, Psychological (19) Multiple Sclerosis (19) Pulmonary Disease, Chronic Obstructive (19) Respiratory Aspiration (19) Thromboembolism (19) Embolism (18) Lung Diseases, Obstructive (18) Pulmonary Fibrosis (18) HIV Infections (17) Kidney Diseases (17) Stroke (17) Blood Coagulation Disorders (16) Heart Failure (16) Hemostatic Disorders (16) Pulmonary Embolism (16) Arthritis, Rheumatoid (15) Asthma (15) Chronic Disease (15) Heart Diseases (15) Lung Diseases, Interstitial (15) Lung Neoplasms (15) Myocardial Infarction (15) Substance-Related Disorders (15) Autism Spectrum Disorder (14) Chronic Pain (14) Crohn Disease (14) Brain Injuries (13) Diabetes Mellitus, Type 1 (13) Infarction (13) Venous Thrombosis (12) Autistic Disorder (11) Carcinoma (11) Colitis (11) Colitis, Ulcerative (11) Dyspnea (11) Feeding and Eating Disorders (11) Obesity (11) Rheumatic Diseases (11) Ulcer (11) Alzheimer Disease (10) Burnout, Professional (10) Leukemia (10) Lymphoma (10) Myocarditis (10) Overweight (10) Parkinson Disease (10) Pregnancy Complications (10) Renal Insufficiency, Chronic (10) Respiratory Syncytial Virus Infections (10) Sepsis (10) Brain Injuries, Traumatic (9) Collagen Diseases (9) Coronary Artery Disease (9) Cystic Fibrosis (9) Dementia (9) Depression, Postpartum (9) Frailty (9) Inflammatory Bowel Diseases (9) Liver Diseases (9) Musculoskeletal Pain (9) Pneumonia, Ventilator-Associated (9) Pulmonary Valve Insufficiency (9) Renal Insufficiency (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Weight Loss (9) Alcohol Drinking (8) Alcoholism (8) Hematologic Neoplasms (8) Infertility (8) Ischemia (8) Parasomnias (8) Problem Behavior (8) Psychotic Disorders (8) RNA Virus Infections (8) Breast Neoplasms (7) Convalescence (7) Coronary Disease (7) Dyssomnias (7) Fatigue (7) Metabolic Syndrome (7) Migraine Disorders (7) Myocardial Ischemia (7) Neoplasm Metastasis (7) Psoriasis (7) Schizophrenia (7) Shock (7) Spinal Cord Injuries (7) Toxemia (7) Acute Coronary Syndrome (6) Brain Diseases (6) Bronchiectasis (6) Carcinoma, Non-Small-Cell Lung (6) Child Development Disorders, Pervasive (6) Colorectal Neoplasms (6) Deglutition Disorders (6) Delirium (6) Disease Susceptibility (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Kidney Failure, Chronic (6) Lupus Erythematosus, Systemic (6) Lymphopenia (6) Multiple Organ Failure (6) Neurologic Manifestations (6) Osteoarthritis (6) (6) Pediatric Obesity (6) Prostatic Neoplasms (6) Sleep Apnea Syndromes (6) Sleep Apnea, Obstructive (6) Appendicitis (5) Arthritis, Psoriatic (5) Autoimmune Diseases (5) Coronaviridae Infections (5) Cross Infection (5) Depressive Disorder, Major (5) Dermatitis (5) Disseminated Intravascular Coagulation (5) Fibromyalgia (5) Gastroparesis (5) Head and Neck Neoplasms (5) Hypersensitivity (5) Idiopathic Pulmonary Fibrosis (5) Leukemia, Lymphoid (5) Metabolic Diseases (5) Mobility Limitation (5) Nervous System Diseases (5) Occupational Stress (5) Osteoarthritis, Knee (5) Pancreatic Neoplasms (5) Premature Birth (5) Triple Negative Breast Neoplasms (5) Acquired Immunodeficiency Syndrome (4) Acute Disease (4) Adenoviridae Infections (4) Amyotrophic Lateral Sclerosis (4) Anemia, Sickle Cell (4) Arrhythmias, Cardiac (4) Asymptomatic Diseases (4) Atrial Fibrillation (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Carcinoma, Renal Cell (4) Cognition Disorders (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Dermatitis, Atopic (4) Digestive System Diseases (4) Eczema (4) Embolism and Thrombosis (4) Endometriosis (4) Gastrointestinal Diseases (4) Headache (4) Heart Arrest (4) Hematologic Diseases (4) Hemophilia A (4) Hemorrhage (4) Hypertension, Pulmonary (4) Intestinal Diseases (4) Liver Cirrhosis (4) Macular Degeneration (4) Malnutrition (4) Motor Neuron Disease (4) (4) Mycobacterium Infections (4) Panic Disorder (4) Peripheral Arterial Disease (4) Postoperative Complications (4) Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Initiation and Maintenance Disorders (4) Spondylarthritis (4) Systemic Inflammatory Response Syndrome (4) Thrombophilia (4) Tobacco Use Disorder (4) Vascular Diseases (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Apnea (3) Bacteremia (3) Bacterial Infections (3) Bulimia (3) Cardiomyopathies (3) Celiac Disease (3) Cerebral Palsy (3) Chilblains (3) Common Cold (3) Congenital Abnormalities (3) Developmental Disabilities (3) Dysgeusia (3) Endocrine System Diseases (3) Eye Diseases (3) Fatigue Syndrome, Chronic (3) Fatty Liver (3) Fever (3) Fistula (3) Fractures, Bone (3) Ganglion Cysts (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Heart Defects, Congenital (3) Hepatitis C (3) Huntington Disease (3) Hyperglycemia (3) Hypothermia (3) Kidney Calculi (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Leukemia, Myeloid, Acute (3) Macular Edema (3) Measles (3) Melanoma (3) Meningitis (3) Mouth Diseases (3) Mucocutaneous Lymph Node Syndrome (3) Multiple Myeloma (3) Multiple Sclerosis, Relapsing-Remitting (3) Myelodysplastic Syndromes (3) Myeloproliferative Disorders (3) Neoplasms, Plasma Cell (3) Neuroendocrine Tumors (3) Non-alcoholic Fatty Liver Disease (3) Obesity, Morbid (3) Obstetric Labor, Premature (3) Ovarian Neoplasms (3) Paramyxoviridae Infections (3) Peripheral Nervous System Diseases (3) Peripheral Vascular Diseases (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psychological Trauma (3) Pulmonary Edema (3) Rare Diseases (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Seizures (3) Shock, Septic (3) Sleep Wake Disorders (3) Small Cell Lung Carcinoma (3) Suicidal Ideation (3) Tachycardia (3) Taste Disorders (3) Tuberculosis (3) Ageusia (2) Agoraphobia (2) Alcoholic Intoxication (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Angina Pectoris (2) Anxiety, Separation (2) Aortic Valve Stenosis (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrophy (2) Back Pain (2) Behcet Syndrome (2) Binge-Eating Disorder (2) Bipolar Disorder (2) Bronchitis (2) Bronchitis, Chronic (2) Bronchopulmonary Dysplasia (2) Caliciviridae Infections (2) Carcinoma, Small Cell (2) Carcinoma, Squamous Cell (2) Cataract (2) Cholangitis (2) Clinical Deterioration (2) Clostridium Infections (2) Communicable Diseases, Emerging (2) Communication Disorders (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Conjunctivitis (2) Depressive Disorder, Treatment-Resistant (2) Diabetic Nephropathies (2) Diabetic Neuropathies (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Emphysema (2) Endocarditis (2) Epilepsy (2) Facies (2) Fractures, Stress (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Genetic Predisposition to Disease (2) Glioblastoma (2) Gout (2) Healthcare-Associated Pneumonia (2) Heart Failure, Systolic (2) Hepatitis (2) Hepatitis A (2) Humeral Fractures (2) Hyperkinesis (2) Hyperphagia (2) Hyperplasia (2) Hypertension, Pregnancy-Induced (2) Hypotension (2) Hypoventilation (2) Infertility, Male (2) Intervertebral Disc Degeneration (2) Ischemic Attack, Transient (2) Jaundice (2) Joint Diseases (2) Leukemia, Myeloid (2) Low Back Pain (2) Lymphedema (2) Lymphoma, B-Cell (2) Lymphoma, Mantle-Cell (2) Lymphoproliferative Disorders (2) Meningitis, Meningococcal (2) Mood Disorders (2) Mucositis (2) Muscle Spasticity (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myofascial Pain Syndromes (2) Myositis (2) Necrosis (2) Nephrolithiasis (2) Nerve Degeneration (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Oropharyngeal Neoplasms (2) Pain (2) Pain, Postoperative (2) Pancreatitis (2) Paresis (2) Periodontal Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Bacterial (2) Pneumonia, Pneumocystis (2) Pre-Eclampsia (2) Preleukemia (2) Pulmonary Eosinophilia (2) Purpura, Thrombocytopenic, Idiopathic (2) Recurrence (2) Respiratory Sounds (2) Rupture (2) Sarcoidosis (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Spinal Diseases (2) Sprains and Strains (2) Squamous Cell Carcinoma of Head and Neck (2) Stillbirth (2) Stomatitis (2) Suicide (2) Temporomandibular Joint Disorders (2) Temporomandibular Joint Dysfunction Syndrome (2) Thoracic Diseases (2) Thrombocytopenia (2) Thyroid Diseases (2) Trauma and Stressor Related Disorders (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Wet Macular Degeneration (2) Yellow Fever (2) Abortion, Spontaneous (1) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Aggression (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Altitude Sickness (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia (1) Anemia, Aplastic (1) Anemia, Iron-Deficiency (1) Aneurysm (1) Aneurysm, Ruptured (1) Angina, Stable (1) Angioedema (1) Angioedemas, Hereditary (1) Ankle Fractures (1) Anorexia (1) Anorexia Nervosa (1) Arachnoiditis (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Barotrauma (1) Biliary Tract Neoplasms (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bone Marrow Diseases (1) Bradycardia (1) Brain Concussion (1) Brain Neoplasms (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Brucellosis (1) Bruxism (1) Bulimia Nervosa (1) (1) Calculi (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Carcinoma, Ovarian Epithelial (1) Cardiotoxicity (1) Cardiovascular Abnormalities (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chorea (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Colitis, Ulcerativ (1) Colonic Diseases (1) (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronary Restenosis (1) Coronary Stenosis (1) (1) Coronavirus Infect (1) Cough (1) Coxsackievirus Infections (1) Crohn Dise (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dehydration (1) Dental Calculus (1) Dental Plaque (1) DiGeorge Syndrome (1) Diabetic Foot (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Drug Overdose (1) Dry Eye Syndromes (1) Dysentery, Bacillary (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Eclampsia (1) Emergence Delirium (1) Encephalitis (1) Endophthalmitis (1) Endotoxemia (1) Enterocolitis (1) Enterocolitis, Pseudomembranous (1) Enuresis (1) Eosinophilic Esophagitis (1) Epstein-Barr Virus Infections (1) Escherichia coli Infections (1) Esophageal Fistula (1) Esophageal and Gastric Varices (1) Esophagitis (1) Esophagitis, Peptic (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Food Hypersensitivity (1) Foot Ulcer (1) Fractures, Closed (1) Gait Disorders, Neurologic (1) Gambling (1) Gastrointestinal Stromal Tumors (1) Gaucher Disease (1) Genetic Diseases, Inborn (1) Geographic Atrophy (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Glomerulonephritis, IGA (1) Glomerulonephritis, Membranous (1) Guillain-Barre Syndrome (1) Halitosis (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis B (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Hodgkin Disease (1) Hot Flashes (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperkalemia (1) Hyperphosphatemia (1) Hypersensitivity, Immediate (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Iatrogenic Disease (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infectious Mononucleosis (1) Infertility, Female (1) Intellectual Disability (1) Intermittent Claudication (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Keratoconjunctivitis (1) Keratoconjunctivitis Sicca (1) Keratosis (1) Keratosis, Actinic (1) Language Disorders (1) Leishmaniasis (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Leukemia, Prolymphocytic (1) Leukemia, Prolymphocytic, T-Cell (1) Lichen Sclerosus et Atrophicus (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Lung Ne (1) Lyme Disease (1) Lymphocytosis (1) Lymphoma, Large B-Cell, Diffuse (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) May-Thurner Syndrome (1) Memory Disorders (1) Meningococcal Infections (1) Meningomyelocele (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth, Edentulous (1) Movement Disorders (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myelodysplastic-Myeloproliferative Diseases (1) Myocardial Reperfusion Injury (1) Nasal Polyps (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplasms, Germ Cell and Embryonal (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Neurobehavioral Manifestations (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Oligospermia (1) Opioid-Related Disorders (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis (1) Otitis Media (1) Otitis Media with Effusion (1) Overwei (1) Pain, Intractable (1) Pain, Procedural (1) Papillomavirus Infections (1) Paraproteinemias (1) Parkin (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Pocket (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pneumon (1) Polyps (1) Pregnancy in Diabetics (1) Presbyopia (1) Primary Dysautonomias (1) Primary Myelofibrosis (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Protein-Energy Malnutrition (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Heart Disease (1) Rabies (1) Radiculopathy (1) Rectal Fistula (1) Rectal Neoplasms (1) Reperfusion Injury (1) Resp (1) Respiratory Distre (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Restless Legs Syndrome (1) Retinal Vein Occlusion (1) Rhinitis (1) Rhinitis, Allergic (1) Rhinitis, Allergic, Seasonal (1) Sarcoma (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) Scleroderma, Localized (1) (1) Self-Injurious Behavior (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Shoulder Fractures (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Speech Sound Disorder (1) Spina Bifida Cystica (1) Spinal Cord Diseases (1) Spinal Dysraphism (1) Spinal Stenosis (1) Spondylitis (1) Spondylitis, Ankylosing (1) Spondylolisthesis (1) Status Epilepticus (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Synovial Cyst (1) Tachycardia, Sinus (1) Tachycardia, Supraventricular (1) Tachycardia, Ventricular (1) Tachypnea (1) Thalassemia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tissue Adhesions (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Meningeal (1) Tuberculosis, Pulmonary (1) Urinary Bladder Neoplasms (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urogenital Neoplasms (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Venous Insufficiency (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Von Willebrand Diseases (1) Vulvar Lichen Sclerosus (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D006948: Hyperkinesis

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug817 COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection Wiki 1.00
drug412 Atomoxetine hydrochloride Wiki 0.71
drug1821 Guanfacine hydrochloride (SPD503) Wiki 0.71
Name (Synonyms) Correlation
drug2188 Interview by psychologists Wiki 0.71
drug3195 Placebo Wiki 0.03

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D001289 Attention Deficit Disorder with Hyperactivity NIH 0.71
D002659 Child Development Disorders, Pervasive NIH 0.29
D001321 Autistic Disorder NIH 0.21
Name (Synonyms) Correlation
D000067877 Autism Spectrum Disorder NIH 0.19
D004194 Disease NIH 0.11

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0002487 Hyperkinetic movements HPO 1.00
HP:0007018 Attention deficit hyperactivity disorder HPO 0.71
HP:0000717 Autism HPO 0.21
Name (Synonyms) Correlation
HP:0000729 Autistic behavior HPO 0.19

Clinical Trials

Navigate: Correlations   HPO

There are 2 clinical trials


1 A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder

This interventional multicenter dose-optimization Phase IV PASS conducted in Europe and the USA evaluates the comparative long-term safety and efficacy of SPD503 in children and adolescents aged 6 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) for whom stimulants are not suitable, not tolerated, or shown to be ineffective. The study will be conducted in two parts: Study Part A (randomized, double-blinded, parallel-group, placebo- and active comparator-controlled, 3-treatment arm safety and efficacy evaluation of SPD503) and Study Part B (open label SPD503 treatment).

NCT04085172
Conditions
  1. Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
  1. Drug: Guanfacine hydrochloride (SPD503)
  2. Drug: Atomoxetine hydrochloride
  3. Other: Placebo
MeSH:Hyperkinesis Attention Deficit Disorder with Hyperactivity
HPO:Attention deficit hyperactivity disorder Hyperactivity Hyperkinetic movements

Primary Outcomes

Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. The RTI task of CANTAB involves elements of decision-making and attention as measured by choice accuracy as well as motor responses, by measuring motor and mental response speeds, and assesses movement time, reaction time, response accuracy, and impulsivity. This outcome measure will be assessed at Week 10 in both Part A and Part B of the study.

Measure: Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 10

Time: Baseline, Week 10

Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. The RTI task of CANTAB involves elements of decision-making and attention as measured by choice accuracy as well as motor responses, by measuring motor and mental response speeds, and assesses movement time, reaction time, response accuracy, and impulsivity. This outcome measure will be assessed at Week 18 in Part A of the study.

Measure: Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 18

Time: Baseline, Week 18

Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. The RTI task of CANTAB involves elements of decision-making and attention as measured by choice accuracy as well as motor responses, by measuring motor and mental response speeds, and assesses movement time, reaction time, response accuracy, and impulsivity. This outcome measure will be assessed at Week 49 in both Part A and Part B of the study.

Measure: Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 49

Time: Baseline, Week 49

Secondary Outcomes

Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. Cognitive domain, sustained attention will be measured by the CANTAB RVP task. RVP measures the ability to sustain attention over time and is a sensitive measure of frontal-parietal function. In this task, single digits appear in a pseudo--random order at a rate of 100 digits per minute in a box at the center of the screen. Participants are to detect a 3-digit target sequence (e.g. 2-4-6) and respond by pressing a button at the bottom of the screen when the final number of the sequence appears on the screen.

Measure: Change from Baseline in the Rapid Visual Information Processing (RVP) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments, SWM is a component of cognitive executive function which is measured by SWM task of CANTAB between the errors. The ability to retain spatial information and manipulate remembered items in working memory will be measured with the SWM task of CANTAB which is self-ordered and assesses the individual's ability to strategize heuristically. The test is a sensitive measure of frontal lobe and executive dysfunction.

Measure: Change from Baseline in the Spatial Working Memory (SWM) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments.Response control or inhibition cognitive domain will be measured by the CANTAB SST. SST measure response inhibition. The participant must respond to an arrow stimulus by touching either of 2 choices depending on the direction the arrow points. If an audio tone is present, the participant is not to respond.

Measure: Change from Baseline in the Stop Signal Task (SST) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. Recognition memory of cognition domain will be measured by the CANTAB DMS task. DMS measures both simultaneous matching and short-term visual memory. The participant is shown a complex visual pattern (the sample) and after a brief delay, 4 similar patterns. The participant must identify the pattern that matches the sample.

Measure: Change from Baseline in the Delayed Matching to Sample (DMS) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

Description: Sexual maturation will be measured by Tanner stage. The stage of puberty or sexual maturation will be evaluated for each participant according to Tanner staging. The Tanner stage for genitals (male, stages I-V), breasts (females, stages I-V), and pubic hair (both sexes, stages I-V) will be documented at the specified times.

Measure: Tanner Stage in Both Part A and Part B at Specified Time Points

Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

Description: Physical examinations will include height and weight. Growth will be measured by weight, height, and BMI. Body mass index is a measure of body fat based on height and weight. Vital signs will be assessed based on blood pressure, pulse rate, respiratory rate and body temperature in both Part A and Part B. The HR, PR interval, QRS interval, and QT interval will be measured from all ECGs and the QTcB and QTcF assessed at specified time points in both Part A and Part B of the study.

Measure: Number of participants with clinically significant changes in Vital signs, ECG, Physical Examination

Time: From start of study drug administration up to follow up (week 52)

Description: Psychiatric symptoms will be measured by the Brief Psychiatric Rating Scale for Children (BPRS-C) total score. The 21 items of the clinician-rated BPRS-C are grouped into the following 7 scales: depression, anxiety, psychomotor excitation, behavior problems, withdrawal retardation, thinking disturbance, and organicity. Each item of the 21 items is clinician-graded using the following 7-point severity Likert-scale from 0 to 6 (not present=0; very mild=1; mild=2; moderate=3; moderately severe=4; severe=5; extremely severe=6. BPRS-C will be assessed at specified time points in both Part A and Part B.

Measure: Brief Psychiatric Rating Scale for Children (BPRS-C)

Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

Description: The C-SSRS is a structured tool to assess suicidal ideation and behavior. A maximum of 19 items will be completed as follows: 7 items are required, a potential 10 additional items will be completed upon a positive response to a required item, and 2 items completed if suicide or suicide-like behavior is observed during the interview. The C-SSRS uses dichotomous scales (i e, yes or no), Likert scales, and text or narrative to further describe thoughts or behaviors. C-SSRS Score will be assessed at specified time points in both Part A and Part B.

Measure: Columbia- Suicide Severity Rating Scale (CSSRS)

Time: Baseline (from start of study drug administration) to Week 52

Description: UKU rating scale was developed for clinicians to assess side effects of psychopharmacological medications based on interviews and other relevant source information. UKU items relevant to the established safety profile of SPD503 such as Increased Duration of Sleep, Asthenia or Lassitude or lncreased Fatigability, Sleepiness or Sedation, and Orthostatic Dizziness. UKU rating scale will be assessed at specified time points in both Part A and Part B.

Measure: Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale

Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36, Week 49, Week 50, Week 51 and Week 52 Part B: Baseline, Week 10, Week 23, Week 36, Week 49, Week 50, Week 51 and Week 52

Description: Sedative effects will be measured by participant ratings on the Pediatric Daytime Sleepiness Scale (PDSS). The PDSS is a self-reported assessment of daytime sleepiness in children aged 11 to 15 years. PDSS questionnaire was designed to be easy to administer, score, and interpret. Sleepiness-related questions are based on previous research of situations that can be sensitive to sleep loss in this age group. The 8 questions are scored on Likert-scale from 0 to 4 (never=0; seldom=1; sometimes=2; frequently=3; always=4). The total score on the PDSS can range from 0 (never sleepy) to 32 (always sleepy). PDSS will be assessed at specified time points in both Part A and Part B.

Measure: Pediatric Daytime Sleepiness Scale (PDSS)

Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

Description: The ADHD-RS-5 (DuPaul et al., 2016) is used widely by mental health, educational, and medical practitioners in screening, diagnosis, and treatment evaluation to determine the frequency and severity of ADHD symptoms and impairments in children and adolescents. Attention-deficit/hyperactivity disorder symptoms is measured by the investigator-administered ADHD Rating Scale-5 (ADHD-RS-5) total score and hyperactivity/impulsivity and inattentiveness symptoms as subscale scores. The ADHD-RS-5 is based on the diagnostic criteria for ADHD as described in the DSM-5 and consists of 2 symptom subscales, inattention and hyperactivity-impulsivity, each with 9 items and a total scale of 18 items. Each item in the subscale is scored with a value ranging from 0 (no symptoms) to 3 (severe symptoms). The total score can range from 0 to 54. ADHD-RS-5 Total Score and Subscales wiil be assessed at specified time points in both Part A and Part B.

Measure: ADHD Rating Scale-5 (ADHD-RS-5) Total Score and Subscales

Time: Part A: Baseline, Week 1, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

Description: Global clinical measurement of ADHD improvement as measured by Clinical Global Impression-Improvement (CGI-I) using the Clinical Global Impression-Severity (CGI-S) to establish baseline. The CGI scale will be used to evaluate the severity of mental illness over time. The CGI-S will be administered to assess the severity of mental illness at baseline. The CGI-S is scored on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). The CGI-I is also scored on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). CGI-I will be measured at specified time points in both Part A and Part B.

Measure: Clinical Global Impression-Improvement (CGI-I)

Time: Part A: Week 1, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Week 10, Week 23, Week 36 and Week 49

Description: The Parent Report Form of the Child Health and Illness Profile - Child Edition (CHIP-CE:PRF) will be administered to provide information on self-esteem and school functioning in pediatric participants diagnosed with ADHD. The 5 domains and 12 subdomains covered in the 76 items comprising the CHIP-CE:PRF. Satisfaction: with health (7 items) and self (4 items); Comfort: physical (9 items) and emotional symptoms (9 items) and activity restrictions (4 items) due to illness; Resilience: behaviors and family involvement (8 items) in activities likely to enhance health, Social problem-solving (5 items),Physical activity (6 items); Risk avoidance: behaviors that if not avoided are likely to pose risks to health: Individual risk avoidance (4 items), Threats to achievement (10 items); Achievement: developmentally appropriate role functioning in school and with peers: Academic performance (5 items), Peer relations (5 items). CHIP-CE: PRF will be assessed in both Part A and Part B.

Measure: Child Health and Illness Profile - Child Edition: Parent Report Form (CHIP-CE:PRF)

Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

Description: School performance will be measured by teacher ratings of academic skills using the APRS at specified time points in both Part A and Part B. The APRS is a reliable rating scale that has been shown to be valid in assessing teacher perceptions of the quality of a student's academic competency. The scale includes 19 items that are directed toward work performance in various participant areas; academic success, behavioral control in academic situations, and attention to assignments. Teachers mark responses in a Likert-scale format from 1 (never or poor) to 5 (very often or excellent). From the APRS, a total score and the following 3 subscale scores are calculated: academic success, impulse control, and academic productivity.

Measure: Academic Performance Rating Scale (APRS)

Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49
2 Clinical Evolution and Parenting in Children and Adolescents With Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Quarantined Because of Covid-19 Outbreak

In response to the coronavirus disease 2019 (covid-19) outbreak, the home confinement of the population ordered by governments in many countries raise questions about its impact on individuals' physical and mental health in the short and longer term. In children, reduced physical activity, changes in lifestyle, disturbances in sleep patterns, lack of in-person contact with peers, poor or inadequate understanding of health risks may be risk factors of anxiety, stress, fatigue, sleep disorders (Brooks et al, 2020; Wang et al, 2020; Sprang et al, 2013). These problematic effects could be modulated by social factors (housing in urban or rural areas, availability of personal space at home, parenting stress, etc.) (Cluver et al, 2020; Liu et al, 2020).

NCT04416360
Conditions
  1. Autism Spectrum Disorder
  2. Attention-deficit Hyperactivity Disorder
Interventions
  1. Other: Interview by psychologists
MeSH:Hyperkinesis Disease Autistic Disorder Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder Child Development Disorders, Pervasive
HPO:Attention deficit hyperactivity disorder Autism Autistic behavior Hyperactivity Hyperkinetic movements

Primary Outcomes

Description: composition, home confinement, change in the environment, personal room at home, screens with internet access, parents' current professional status, teleworking, care, family concerns related to Covid-19, parenting stress, schooling, recurrent complaints.

Measure: Interview of the parents : contextual data

Time: Baseline

Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

Time: Baseline

Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

Time: 1 month

Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

Time: 3 months

Description: Data relating to disease and management of care. Experience of the referring caregiver.

Measure: Interview of the referring caregiver : data relating to disease and management of care

Time: 3 months

HPO Nodes


HP:0000752: Hyperactivity
Genes 603
EZR TGIF1 MBD5 SH2B1 EEF1A2 KCNA1 GNE TBL1X ALG13 HSPG2 NODAL GNE CUL4B POLA1 DHCR7 NSUN2 AGTR2 AMT ZNF711 GTF2IRD1 SLC9A7 NECAP1 PIGY RAB39B PHF21A FRMPD4 CNKSR2 SATB2 KIF11 SHH ARX NTRK1 GABRG2 ST3GAL3 ARVCF SLITRK1 SETD5 MED13 YY1 RREB1 GNB5 GCSH TRAPPC14 DNM1 STXBP1 FBXO11 STEEP1 ARX HUWE1 AIMP1 ATP10A UBE3A AARS1 PIEZO2 FGF8 DMD RAB39B GAS1 EBP TGFBR2 FOXH1 CLIP2 ELN GRIN2A FANCD2 MYT1L HIRA CC2D1A GP1BB SVBP ACTL6B ADNP DLL1 SEC24C SIX3 CDK8 TIMM8A GABRG2 ELN PIK3CA HCN1 PAH MBOAT7 CLTC SATB2 TLK2 WAC GNS PMS2 FOXH1 CLCN4 GABRA5 TTI2 AFF2 GABRG2 CDON TSC1 GDI1 SLC1A2 PTCHD1 GAS1 PDE4D SHOC2 HDC GABRB2 CREBBP NPAP1 KMT2A PTCH1 FRRS1L OPHN1 CC2D1A KRAS JRK SCN1A NTRK2 CDON CDK19 KMT2E IGF2 SHH DISP1 ASPM TANC2 STS ZIC2 NFIX ACTL6B SNORD115-1 LIG4 GALC MADD NF1 DISP1 MAN1B1 FGD1 ARG1 KCNB1 PAK3 MKRN3-AS1 FOXH1 TSPAN7 YWHAG SEMA3E TDGF1 IKBKG KDM5B DHTKD1 FAN1 TKT VPS13A FTSJ1 MED13 NBN GLI2 FGF8 ABCD1 ANK3 YWHAG PPM1D CNKSR2 DPYD GRIA4 PNKP FGFR1 IGF1 ZNF81 SMARCC2 PUF60 CCBE1 PDE4D TAF1 KMT2A PWRN1 IPW HOXA2 PNKP CHRNA7 FLI1 PAK3 WDR62 SNRPN DISP1 DALRD3 PANK2 SPR TRIO STAG2 ARID2 KCNA2 ADSL SIX3 DNAJC21 RAI1 SH2B1 EBP KDM6B ZC3H14 DCPS MED12 HTT HNMT NKAP MSH6 BSCL2 DMXL2 KIF15 ZIC2 WDFY3 KIF14 CACNA1H HERC2 GABRA2 ACY1 MSH2 MED23 CAMTA1 DHCR7 FGF8 NTRK1 SHH SYNGAP1 CREBBP DYM RIC1 NOP56 FGFR3 NODAL AP3B2 DDX6 PTCH1 ZIC2 RAD21 NUS1 SOX5 TTI2 MED25 ADAT3 KANSL1 DLL1 LINS1 WASHC4 RERE CASK SLC6A8 FGF12 DNM1 ODC1 KAT8 TUSC3 BCORL1 MAGEL2 ACSL4 PCNT TET3 STS CLTC CDON SPRED1 NSDHL MID2 SIK1 CDKN1C STAG2 PPP1R12A SLC13A5 FBXW11 ALDH5A1 PTCH1 SLC45A1 GATAD2B PSMD12 GLI2 ANAPC1 PWAR1 SLC1A4 TRIP12 WAC SCN8A ASH1L AASS SLC2A1 THRB CNKSR2 TSC2 KANSL1 GLUD1 MAPK1 CARS1 IFNG NIPBL TCF20 USP9X MKRN3 CUX2 PANK2 FGFR1 DLL1 NSUN2 RAI1 TCF20 TECR OPHN1 TAF6 PCGF2 FLCN B3GALNT2 BCAP31 DYRK1A RPS20 MID2 FMR1 PAH CUL4B SNRPN PRODH HAL MED12 SHANK3 CSGALNACT1 ADAT3 IL1RAPL1 APC2 TNIK APC2 ODC1 CNTNAP2 CACNA1A TBX1 NSD1 JMJD1C C12ORF4 CREBBP RSRC1 TBX1 FBXO31 SHROOM4 NRXN1 PNP TSHR EPCAM MECP2 TNIK TBL2 SIM1 TBX1 WWOX GABRB3 SYNJ1 METTL5 DNAJC12 PRNP TUBB2B SATB2 NEXMIF CSNK2A1 MTOR FOXP1 CLIP1 RFC2 GLDC TMCO1 SARS1 GATA4 TRAPPC9 SNORD116-1 LIMK1 MED12 MYT1L CRBN PPP2R1A SIX3 PTCHD1 CRBN EP300 ATP6V1A GLI2 SMPD1 BSCL2 ARV1 CRKL EP300 CDKL5 PMS1 SZT2 MCTP2 BPTF SIN3A NEUROD2 SYP CDON ZMIZ1 TBX1 ZNF41 PRSS12 PIGP DDX3X SMC1A STEEP1 IQSEC2 CACNA1B CIC LNPK ATRX GABRB3 EDC3 UBE3A ACTL6A DEAF1 NSDHL MED12 PLA2G6 ZIC2 CLCN4 UBE3A PSMD12 SCN8A PCDH19 MLH1 SLC6A8 GABRA1 FOXH1 USP27X UBTF FGD1 KCNK9 TSC2 RAI1 PHIP GRIN2D MECP2 FGF8 GRIK2 SNRPN NDP NBN PRKCG NDST1 TANC2 TGIF1 ATP1A1 NLGN1 WAC POGZ UBE3A ZMIZ1 SMC1A PUS7 HDAC4 MANBA SLC25A13 TDGF1 TSC1 KRAS HMGA2 TRAPPC9 ATR PTCH1 IQSEC1 CNTNAP2 GLI2 TSHR SEMA4A GAS1 PPP3CA GAS1 TRIM8 DOCK3 ANK3 SETBP1 GABRB3 UFD1 TGIF1 SLC1A4 SH3KBP1 PLAG1 DPP6 GTF2I SCN2A STAG2 SHANK3 FMR1 ATRX HGSNAT KDM3B GNAQ CYFIP2 KCNA2 LMAN2L RUSC2 MED13L FRMPD4 KANSL1 AFF2 GRIN2A PTCH1 NR2F1 TRAK1 PIGC MAPK10 UBA5 SETD5 TDGF1 ZSWIM6 UQCC2 CHD2 RAI1 MED12L SCN1B DYRK1A PARS2 TGIF1 BMPR1A CHD7 STXBP1 ARF1 UPF3B ALKBH8 SMC1A CDH2 NDN SETD2 INPP5E UPF3B OCRL DHDDS TSHR METTL23 HCFC1 SHROOM4 SMC3 YME1L1 HIVEP2 TDGF1 ADNP ZDHHC9 IQSEC1 NAGLU DLL1 PGAP1 TRMT1 SHH DPH1 SIX3 RERE SLC25A22 TKT HDAC8 MLH3 HERC2 CORO1A SRPX2 STAG2 DLG3 DRD5 EP300 C12ORF4 MLXIPL FMN2 MAP1B IQSEC2 DDX3X GATAD2B BCR RSRC1 SETBP1 NKX2-1 SPG7 SCN3A GNAO1 LHCGR BCORL1 NODAL NTNG2 SGSH BAZ1B DLL1 TRAPPC4 GAMT MED12 COMT CRADD USP7 DRD4 FLII NTNG1 ARHGEF6 FOXP1 DYNC1I2 NODAL RPS6KA3 PRKAR1A AUTS2 RLIM TRIO DPF2 PAH ABCD1 PIGQ IL1RAPL1 IGF1 OCA2 DISP1
Protein Mutations 0
SNP 0

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0000752: Hyperactivity
Genes 603
EZR TGIF1 MBD5 SH2B1 EEF1A2 KCNA1 GNE TBL1X ALG13 HSPG2 NODAL GNE CUL4B POLA1 DHCR7 NSUN2 AGTR2 AMT ZNF711 GTF2IRD1 SLC9A7 NECAP1 PIGY RAB39B PHF21A FRMPD4 CNKSR2 SATB2 KIF11 SHH ARX NTRK1 GABRG2 ST3GAL3 ARVCF SLITRK1 SETD5 MED13 YY1 RREB1 GNB5 GCSH TRAPPC14 DNM1 STXBP1 FBXO11 STEEP1 ARX HUWE1 AIMP1 ATP10A UBE3A AARS1 PIEZO2 FGF8 DMD RAB39B GAS1 EBP TGFBR2 FOXH1 CLIP2 ELN GRIN2A FANCD2 MYT1L HIRA CC2D1A GP1BB SVBP ACTL6B ADNP DLL1 SEC24C SIX3 CDK8 TIMM8A GABRG2 ELN PIK3CA HCN1 PAH MBOAT7 CLTC SATB2 TLK2 WAC GNS PMS2 FOXH1 CLCN4 GABRA5 TTI2 AFF2 GABRG2 CDON TSC1 GDI1 SLC1A2 PTCHD1 GAS1 PDE4D SHOC2 HDC GABRB2 CREBBP NPAP1 KMT2A PTCH1 FRRS1L OPHN1 CC2D1A KRAS JRK SCN1A NTRK2 CDON CDK19 KMT2E IGF2 SHH DISP1 ASPM TANC2 STS ZIC2 NFIX ACTL6B SNORD115-1 LIG4 GALC MADD NF1 DISP1 MAN1B1 FGD1 ARG1 KCNB1 PAK3 MKRN3-AS1 FOXH1 TSPAN7 YWHAG SEMA3E TDGF1 IKBKG KDM5B DHTKD1 FAN1 TKT VPS13A FTSJ1 MED13 NBN GLI2 FGF8 ABCD1 ANK3 YWHAG PPM1D CNKSR2 DPYD GRIA4 PNKP FGFR1 IGF1 ZNF81 SMARCC2 PUF60 CCBE1 PDE4D TAF1 KMT2A PWRN1 IPW HOXA2 PNKP CHRNA7 FLI1 PAK3 WDR62 SNRPN DISP1 DALRD3 PANK2 SPR TRIO STAG2 ARID2 KCNA2 ADSL SIX3 DNAJC21 RAI1 SH2B1 EBP KDM6B ZC3H14 DCPS MED12 HTT HNMT NKAP MSH6 BSCL2 DMXL2 KIF15 ZIC2 WDFY3 KIF14 CACNA1H HERC2 GABRA2 ACY1 MSH2 MED23 CAMTA1 DHCR7 FGF8 NTRK1 SHH SYNGAP1 CREBBP DYM RIC1 NOP56 FGFR3 NODAL AP3B2 DDX6 PTCH1 ZIC2 RAD21 NUS1 SOX5 TTI2 MED25 ADAT3 KANSL1 DLL1 LINS1 WASHC4 RERE CASK SLC6A8 FGF12 DNM1 ODC1 KAT8 TUSC3 BCORL1 MAGEL2 ACSL4 PCNT TET3 STS CLTC CDON SPRED1 NSDHL MID2 SIK1 CDKN1C STAG2 PPP1R12A SLC13A5 FBXW11 ALDH5A1 PTCH1 SLC45A1 GATAD2B PSMD12 GLI2 ANAPC1 PWAR1 SLC1A4 TRIP12 WAC SCN8A ASH1L AASS SLC2A1 THRB CNKSR2 TSC2 KANSL1 GLUD1 MAPK1 CARS1 IFNG NIPBL TCF20 USP9X MKRN3 CUX2 PANK2 FGFR1 DLL1 NSUN2 RAI1 TCF20 TECR OPHN1 TAF6 PCGF2 FLCN B3GALNT2 BCAP31 DYRK1A RPS20 MID2 FMR1 PAH CUL4B SNRPN PRODH HAL MED12 SHANK3 CSGALNACT1 ADAT3 IL1RAPL1 APC2 TNIK APC2 ODC1 CNTNAP2 CACNA1A TBX1 NSD1 JMJD1C C12ORF4 CREBBP RSRC1 TBX1 FBXO31 SHROOM4 NRXN1 PNP TSHR EPCAM MECP2 TNIK TBL2 SIM1 TBX1 WWOX GABRB3 SYNJ1 METTL5 DNAJC12 PRNP TUBB2B SATB2 NEXMIF CSNK2A1 MTOR FOXP1 CLIP1 RFC2 GLDC TMCO1 SARS1 GATA4 TRAPPC9 SNORD116-1 LIMK1 MED12 MYT1L CRBN PPP2R1A SIX3 PTCHD1 CRBN EP300 ATP6V1A GLI2 SMPD1 BSCL2 ARV1 CRKL EP300 CDKL5 PMS1 SZT2 MCTP2 BPTF SIN3A NEUROD2 SYP CDON ZMIZ1 TBX1 ZNF41 PRSS12 PIGP DDX3X SMC1A STEEP1 IQSEC2 CACNA1B CIC LNPK ATRX GABRB3 EDC3 UBE3A ACTL6A DEAF1 NSDHL MED12 PLA2G6 ZIC2 CLCN4 UBE3A PSMD12 SCN8A PCDH19 MLH1 SLC6A8 GABRA1 FOXH1 USP27X UBTF FGD1 KCNK9 TSC2 RAI1 PHIP GRIN2D MECP2 FGF8 GRIK2 SNRPN NDP NBN PRKCG NDST1 TANC2 TGIF1 ATP1A1 NLGN1 WAC POGZ UBE3A ZMIZ1 SMC1A PUS7 HDAC4 MANBA SLC25A13 TDGF1 TSC1 KRAS HMGA2 TRAPPC9 ATR PTCH1 IQSEC1 CNTNAP2 GLI2 TSHR SEMA4A GAS1 PPP3CA GAS1 TRIM8 DOCK3 ANK3 SETBP1 GABRB3 UFD1 TGIF1 SLC1A4 SH3KBP1 PLAG1 DPP6 GTF2I SCN2A STAG2 SHANK3 FMR1 ATRX HGSNAT KDM3B GNAQ CYFIP2 KCNA2 LMAN2L RUSC2 MED13L FRMPD4 KANSL1 AFF2 GRIN2A PTCH1 NR2F1 TRAK1 PIGC MAPK10 UBA5 SETD5 TDGF1 ZSWIM6 UQCC2 CHD2 RAI1 MED12L SCN1B DYRK1A PARS2 TGIF1 BMPR1A CHD7 STXBP1 ARF1 UPF3B ALKBH8 SMC1A CDH2 NDN SETD2 INPP5E UPF3B OCRL DHDDS TSHR METTL23 HCFC1 SHROOM4 SMC3 YME1L1 HIVEP2 TDGF1 ADNP ZDHHC9 IQSEC1 NAGLU DLL1 PGAP1 TRMT1 SHH DPH1 SIX3 RERE SLC25A22 TKT HDAC8 MLH3 HERC2 CORO1A SRPX2 STAG2 DLG3 DRD5 EP300 C12ORF4 MLXIPL FMN2 MAP1B IQSEC2 DDX3X GATAD2B BCR RSRC1 SETBP1 NKX2-1 SPG7 SCN3A GNAO1 LHCGR BCORL1 NODAL NTNG2 SGSH BAZ1B DLL1 TRAPPC4 GAMT MED12 COMT CRADD USP7 DRD4 FLII NTNG1 ARHGEF6 FOXP1 DYNC1I2 NODAL RPS6KA3 PRKAR1A AUTS2 RLIM TRIO DPF2 PAH ABCD1 PIGQ IL1RAPL1 IGF1 OCA2 DISP1
Protein Mutations 0
SNP 0

Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook